Glaukos Corporation

GKOS ·Healthcare, Medical Devices, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Operating Activities
Net Income $-50.5M $-40.8M $-36.8M $-30.4M $-32.8M $-34.6M $-31.5M $-27.6M
Depreciation & Amortization $9.0M $8.9M — — — — $26.9M $1.7M
Depreciation $2.8M $2.7M $2.3M $2.2M $2.2M $2.1M $2.0M $1.7M
Amortization $6.2M $6.2M $6.2M $6.2M $6.2M $6.2M $6.2M $6.2M
Stock-Based Compensation $11.3M $11.2M $13.0M $10.5M $9.9M $10.2M $11.7M $9.4M
Net Cash from Operating Activities $-18.4M $-33.9M $-10.7M $-8.2M $-8.2M $-30.8M $-4.1M $-26.5M
Investing Activities
Capital Expenditures $2.1M $968.0K $4.2M $3.4M $5.8M $6.9M $8.2M $6.0M
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $34.9M $-29.4M $-12.9M $14.9M $26.0M $-13.8M $16.7M $24.4M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $8.6M $13.2M $7.3M $7.5M $-880.0K $1.2M $529.0K $4.2M
Net Change in Cash $24.5M $-51.0M $-15.5M $14.1M $17.2M $-43.1M $13.5M $1.4M
Free Cash Flow $-20.5M $-34.8M $-14.9M $-11.5M $-13.9M $-37.7M $-12.4M $-32.6M
← Newer Page 2 of 6 Older →